Graves' Disease — A Thyroid Overdriven to Make Hormone
An autoimmune signal keeps the thyroid pump running at maximum.
- ~1%: Graves' prevalence (of US adults, lifetime)
- 7:1: Female:male ratio (strong sex skew)
- 50–80%: Baseline uptake (24h) (vs 10–30% normal)
- Suppressed: TSH level (classic hyperthyroid pattern)
Autoimmune drive behind the overactivity
TSI antibodies mimic TSH, locking the receptor on.
Why the gland accumulates iodine so eagerly
The sodium-iodide symporter is upregulated and hyperactive.
Symptoms driving patients to treatment
Tachycardia, weight loss, tremor, heat intolerance, goiter.
Swallowing the Capsule — Radioiodine Enters the Bloodstream
A simple oral dose starts a highly targeted radiologic therapy.
- 10–30 mCi: Typical dose (millicuries, patient-specific)
- 8.0 days: Isotope half-life (physical decay of I-131)
- GI tract: Absorption route (capsule or liquid form)
- Beta + gamma: Radiation type (beta does local damage)
Dose selection logic
Dose scales with gland size, uptake percentage, and severity.
Systemic distribution before uptake
I-131 briefly circulates body-wide before thyroid concentrates it.
Outpatient radiation safety precautions
Brief isolation limits exposure to family and public.
The Symporter Concentrates I-131 Almost Exclusively in Thyroid
The same pump that grabs dietary iodine grabs the radioactive isotope.
- >50:1: Thyroid:blood ratio (concentration gradient)
- ~24–48h: Peak thyroid uptake (post-dose)
- Minimal: Off-target uptake (salivary/gastric trace only)
- ~2 mm: Beta particle range (tissue penetration)
Sodium-iodide symporter mechanics
NIS actively transports iodide against its gradient into cells.
Short beta range spares neighboring organs
Radiation stays largely confined within the gland itself.
Confirming uptake with scintigraphy
Imaging verifies concentrated isotope before/after dosing.
Weeks of Beta Radiation Progressively Ablate Follicular Cells
Radiation damage accumulates slowly, shrinking the gland over months.
- 2–4 wks: Onset of effect (symptoms begin easing)
- ~3–6 mo: Peak shrinkage (gland volume reduction)
- ~40–60%: Mass reduction (typical at 6 months)
- Double-strand breaks: DNA damage mode (beta-induced)
Radiation biology of the ablation
Beta particles fragment DNA, triggering follicular cell death.
Gradual, not immediate, tissue loss
Cell death and clearance unfold over weeks, not days.
Monitoring hormone levels during decline
TSH/T4 checked periodically as function falls.
Hyperthyroidism Resolves — Most Patients Become Hypothyroid
The predictable trade-off: cured hyperthyroidism, lifelong replacement.
- ~70–90%: Hypothyroidism by 1 yr (depending on dose strategy)
- Lifelong: Levothyroxine duration (daily oral replacement)
- >90%: Treatment success rate (single-dose cure of hyperthyroidism)
- ~10–20%: Re-treatment needed (if uptake insufficient)
Why hypothyroidism is the expected endpoint
Ablation deliberately overshoots to guarantee lasting cure.
Levothyroxine replacement therapy
A once-daily pill restores normal hormone levels reliably.
Accepting the trade-off
Predictable hypothyroidism beats unresolved hyperthyroidism.
Placeholder: lifelong levothyroxine is considered an acceptable, well-managed trade-off.